When does dolutegravir’s patent (or exclusivity) expire in India?
The exact “patent expiry” date for dolutegravir in India depends on which specific patent(s) cover the product or its key claims, and on whether there is any additional form of protection (for example, a separate composition patent versus a method-of-use patent). Dolutegravir’s availability in India has been shaped by the presence of multiple patent filings and licensing/authorization arrangements rather than a single universal expiry date.
If you tell me the brand you mean (for example, Triumeq, Tivicay, or a particular generic) or the manufacturer you’re tracking, I can narrow the answer to the relevant Indian patent(s) and their status.
Which Indian patents typically control dolutegravir market exclusivity?
In practice, India’s market control for an antiretroviral like dolutegravir can be tied to different patent families, such as:
- Composition-of-matter patents covering the dolutegravir compound.
- Process patents (how the drug is made).
- Method-of-use patents (how it’s used clinically).
Because these can have different filing dates and term calculations, the “earliest expiry” among the relevant claims may differ from the expiry of the broadest compound patent.
Can generics enter immediately when a dolutegravir patent expires?
Patent expiry is not the only factor. Even after expiry of one patent, a generic launch can still be delayed by:
- Other still-active dolutegravir-related patents (including process or use patents).
- Ongoing litigation or injunctions tied to other claims.
- Regulatory/market approvals that are independent of patent status.
So, the “date generics can enter” may be later than the expiry of a single patent if other protected claims remain in force.
How does India’s 20-year patent term and priority dates affect dolutegravir?
India generally grants patents for 20 years from the filing date (with specific timing rules tied to the priority/filing history of the application). Dolutegravir’s different patent families can therefore expire at different times depending on:
- The earliest priority date for that particular patent family.
- The Indian filing/first filing chronology.
- Any adjustments based on Indian patent-processing events.
That is why locating the specific Indian patent publication numbers you care about is usually required to give a precise expiry date.
What if there are compulsory licences or patent oppositions?
If a compulsory licence was granted for a relevant dolutegravir patent, or if patent grants were challenged (for example, via oppositions or revocation), the practical “effective exclusivity” could end earlier than the nominal term expiry date. These outcomes depend on case-specific decisions and timelines.
If you share details, I can give a precise expiry timeline
To pinpoint dolutegravir patent expiry in India, reply with one of the following:
- The patent/publication number(s) you’re tracking, or
- The innovator company/brand (and which formulation strength), or
- The specific generic maker you mean.
Once I have that, I can map the relevant Indian patent term(s) and identify the earliest date(s) when exclusivity would end based on the available records.
Sources
No sources were provided with your question, so I can’t verify an exact India expiry date from primary records here. If you share the patent numbers/brand, I can answer precisely.